Advanced searches left 3/3

Fatty Liver Disease - DOAJ

Summarized by Plex Scholar
Last Updated: 13 September 2022

* If you want to update the article please login/register

Adipose-derived mesenchymal stem cell-secreted extracellular vesicles alleviate non-alcoholic fatty liver disease via delivering miR-223-3p

The potential of mesenchymal stem cell-derived extracellular vesicles in non-alcoholic fatty liver disease treatment has been increasing investigated. The uptake of isolated ADSC-EVs by hepatocytes was determined, and miR-223-3p expression in ADSC-EVs and hepatocytes was determined. Since E2F1 was identified as a target gene of miR-223-3p, miR-223-3p-based ADSC-EVs containing miR-223-3p had suppressive effects on lipid accumulation and liver fibrosis by E2F1 inhibition, it was seen as a target gene of miR-223-3p. This report, in addition, miR-223-3p-loaded ADSC-EVs, a potential therapeutic option for NAFLD, suggests that ADSC-EVs slowed the progression NAFLD by the introduction of anti-fibrotic miR-223-3p and subsequent E2F1 suppression, which may have spelled NAFLD with miR-223-3p-EVs.

Source link: https://doi.org/10.1080/21623945.2022.2098583


Associations of serum multivitamin levels with the risk of non-alcoholic fatty liver disease: A population-based cross-sectional study in U.S. adults

Vitamins were closely related to non-alcoholic fatty liver disease development, but no research had investigated the relationship of serum multivitamin levels with NAFLD risk. Of the 969 participants, 969 participants in NAFLD were more likely to be male, older, less educated, or have hypertension/high cholesterol/diabetes. After adjustment of covariates, serum VC/VB6/VB9 levels were positively correlated with NAFLD risk, with NAFLD risk, but serum VA/VE levels were positively correlated with NAFLD risk. Increased NAFLD risk in the WQS model, as well as elevated serum VA/VE levels and lower serum VC/VD/VB6 levels were linearly associated with increased NAFLD risk.

Source link: https://doi.org/10.3389/fnut.2022.962705


Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis

BACKGROUNDANCE:Non-alcoholic fatty liver disease (formerly a neglected disease that is now a global pandemic) is a neglected disease. paraphrasedoutput:Methods was a website that published estimates of NAFLD incidence and long-term trends in 1990 to 2019 According to the following criteria: gender, age, socioeconomic index, and geographic location. A better understanding of the disease and subsequent prevention efforts will help to raise public knowledge of the disease and future prevention policies. In 2005, the joinpoint model suggested a new trend of increasing NAFLD incidence in the Midwest. paraphrasedoutput:ConclusionsThe younger birth cohorts of NAFLD were at a reduced risk of NAFLD than previous ones.

Source link: https://doi.org/10.3389/fcvm.2022.891963


The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population

triglyceride glucose-body mass index (IB) had an independent positive relationship with NAFLD, according to some studies. We wanted to see whether TyG-BMI was effective in detecting NAFLD in the general Japanese population in this research. Methods The study was carried out by a cross-sectional analysis of 14,280 people who underwent a comprehensive health exam. According to the preparation and validation groups, TyG-BMI's area was between 0. 888 and 0. 884. Both estimation and validation groups have 77% and 70%, respectively. The presence of NAFLD could be effectively determined by using TyG-BMI's high cutoff, which is the most common diagnostic function of the estimation and validation groups. Conclusions In conclusion, the present research designed and validated a simple, non-invasive, and cost-effective method to clearly distinguish participants with and without NAFLD in the Japanese population, effectively distinguishing participants with and without NAFLD, indicating that ultrasonography for identifying NAFLD is unnecessary in a substantial number of individuals.

Source link: https://doi.org/10.1186/s12967-022-03611-4


Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Nonalcoholic fatty liver disease is common among type 2 diabetes mellitus patients and is associated with an elevated risk of coronary atherosclerosis and acute cardiovascular events. In an intervention study in patients with T2DM and new acute coronary syndrome, we used the validated, non-invasive Angulo NAFLD fibrosis score to determine the relationship between FS and CV risk and treatment reaction to apabetalone. Methods: In 2,425 patients with T2DM and new ACS, the Phase 3 BETonMACE trial compared apabetalone with placebo in comparison to placebo in 2,425 patients with T2DM and recent ACS. We analyzed apabetalone therapy's effect on CV risk in two patient groups of FS that indicate the likelihood of underlying NAFLD in this post-hoc review. Result: 3. 7 percent of patients' FS were elevated and stable, with a moderate to heightened risk of advanced liver fibrosis in 73 percent of patients; 26. 3% of patients had a lower FS — 73. 7% of patients had a higher FS. FS+ patients had a higher risk of ischemic MACE and HHF than FS0-2 patients in the placebo group. In FS+ patients, the addition of apabetalone to the standard of care treatment reduced the incidence of ischemic MACE in comparison with placebo, HHF, and a composite of ischemic MACE and HHF. Conclusions: apabetalone was found to have a significant decline in hepatic FS as a result of time among patients with T2DM, recent ACS, and a moderate to high risk of advanced liver fibrosis.

Source link: https://doi.org/10.1016/j.ajpc.2022.100372


Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease is related to reactive oxygen species manufacturing and oxidative stress, so antioxidant therapy can help avoid any further development. Multiple enzyme-like enzymes have been demonstrated for scavenging oxygen species in Ultrasmall copper-based nanoparticles, providing a new approach to inflammatory disease treatment. Live-targeted nanocarriers loaded with bioactive chemicals may be a more cost-effective treatment of NAFLD. To increase therapeutic effectiveness, Res and the ultrasmall CuNPs were specifically targeted to liver tissue. The combination of these two components can effectively treat inflammation in NAFLD, according to this review, and liver-targeted NAFLD-specific ultrasound nanobubbles that can simultaneously deliver Res and CuNPs may be a safe and effective new platform for NAFLD and other liver diseases.

Source link: https://doi.org/10.3389/fphys.2022.950141


Non-alcoholic fatty liver disease and dairy products consumption: Results from FASA Persian cohort study

Objectives/British Background/ObjectivesThere are no studies on the correlation between dairy product intake and nonalcoholic fatty liver disease. ResultsThe mean age of all participants was 48. 81 years in 2009 and a variety of logistic regression tools was used to measure the mean difference in mean FLI and odds ratios for sub-NAFLD across quantiles of dairy intake. Participants in the third tertile of cheese intake had significantly lower FLI than lower tertiles, according to the tertiles. However, in the multivariate model, there was no relationship between cheese intake and the odds of FLI. Conclusion: We didn't find any significant correlation between yogurt intake and NAFLD results, but there was no conclusive correlation between yogurt intake and NAFLD results. Conclusion:Higher milk intake was inversely related to FLI.

Source link: https://doi.org/10.3389/fnut.2022.962834


Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis

Background Dietary polyphenol therapy of non-alcoholic fatty liver disease is a new step forward, and the existing clinical trials have no valid evidence for its therapeutic use, although some studies have conflicting results. The use of dietary polyphenols in the treatment of NAFLD is still contested. Methods The objective of this research was to determine the therapeutic efficacy of oral dietary polyphenols in patients with NAFLD. Source: PubMed, Cochrane, Medline, CNKI, and other databases on NAFLD treatment with dietary polyphenols. Naringenin significantly reduced the number of NAFLD grade, TG, TC, and low-density lipoprotein cholesterol LDL-C and increased high-density lipoprotein cholesterol HDL-C, while still having no effect on AST and ALT, and it is a safe supplementation. 4 Only one team has developed a protocol involving anthocyanin extracted from Cornus mas L. fruit extract for NAFLD treatment.

Source link: https://doi.org/10.3389/fimmu.2022.949746


Effects of scoparone on non-alcoholic fatty liver disease revealed by RNA sequencing

Scoparone is known to have the curative effect of reducing liver injury. Through in vivo experiments and RNA sequencing, the aim of this research was to determine the therapeutic effect and potential mechanism of SCO against high-fat diet-induced non-alcoholic liver disease caused by high-fat diet-induced non-alcoholic liver disease. For eight weeks, male Kunming mice were fed with HFD to develop a mouse model of NAFLD, and SCO was used to treat NAFLD. HFD could lead to significant steatosis in mice, according to the histopathological study, while SCO could alleviate liver steatosis in NAFLD mice. SCO could reduce the elevated serum transaminase production and liver lipid level induced by HFD, according to the determination of biochemical indicators. The majority of genes involved in cholesterol synthesis and fatty acid metabolism in HFD were reversed by SCO. SCO reduced liver injury and steatosis in NAFLD mice, which may be closely related to cholesterol and fatty acid metabolism control, which may be closely related to cholesterol and fatty acid metabolism.

Source link: https://doi.org/10.3389/fendo.2022.1004284


The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease

Serum uric acid is considered as an independent risk factor for nonalcoholic fatty liver disease. In the First Affiliated Hospital of Sun Yat-Sen University from January 2015 to December 2021, a cross-sectional study included consecutive individuals with ultrasonography and magnetic resonance imaging (u2013)-based proton density fat fraction measurements from January 2015 to December 2021. Patients with higher SUA levels in the NAFLDu2013non-MAFLD group also had higher liver fat levels than those without, according to them, who were using these cutoff numbers. Patients with elevated SUA levels are also at a high risk of severe steatosis, according to the lean/normal-weight NAFLD.

Source link: https://doi.org/10.3390/nu14173587

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions